 The amount of glycosylation affects how the body interacts with the drug and how the drug interacts with the body.At that time, Genetics Institute, Inc. was working on molgramostim, Immunex was working on sargramostim (Leukine), and Sandoz was working on regramostim.Molgramostim was eventually co-developed and co-marketed by Novartis and Schering-Plough under the trade name Leucomax for use in helping white blood cell levels recover following chemotherapy, and in 2002 Novartis sold its rights to Schering-Plough.